Results 71 to 80 of about 6,491 (191)
Palivizumab use in preterm neonates.
, 2010 Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis in infants. Palivizumab is an immunoprophylactic agent for RSV prevention in preterm infants and those with neonatal chronic lung disease. This study examines its use across neonatal
Murphy, B P, Kingston, S
core
Palivizumab em contexto domiciliário [PDF]
, 2012 O Departamento de Pediatria, nomeadamente a UCIENP, através do Projeto de Apoio Domiciliário ao Recém-Nascido internado na UCIEN, formou em 2009, uma equipa multidisciplinar de apoio domiciliário, em parceria com a Fundação do Gil, procurando contribuir ...
Amaral, J, Lopez, M, Costa, M, Cunha, A
core
Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden
, 2004 AIM: Palivizumab (Synagis) was registered in Sweden in 1999 for prophylaxis against respiratory syncytial virus (RSV) in premature infants. The high costs and the limited knowledge of the efficacy of this substance have led to debate about how and when ...
Eriksson, M. +5 more
core +2 more sources
Economic disadvantages of palivizumab [PDF]
Archives of Disease in Childhood, 2000 Editor,—We would fully agree with Dr Sanjeev Deshpande's appraisal of the economic disadvantages of palivizumab ( Arch Dis Child 2000; 82 :88–90) and …
openaire +1 more source
BMC Infectious DiseasesAim Palivizumab has proven effective in reducing hospitalizations, preventing severe illness, improving health outcomes, and reducing healthcare costs for infants at risk of respiratory syncytial virus (RSV) infection.
Jaime E. Ordóñez, Victor M. Huertas
doaj +1 more source
Palivizumab and RSV prevention [PDF]
Archives of Disease in Childhood, 2000 Editor,—The letters from Drs Deshpande and Nicholl, in relation to the Impact-RSV study and the UK guidance for the use of palivizumab in the prevention of serious RSV infections, raise interesting questions that need to be addressed. I believe Dr Deshpande “has got it wrong” in that he fails to realise that the primary objective of the IMpact study ...
openaire +1 more source
Palivizumab use in preterm neonates.
, 2012 Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis in infants. Palivizumab is an immunoprophylactic agent for RSV prevention in preterm infants and those with neonatal chronic lung disease. This study examines its use across neonatal
Murphy, B P, Kingston, S
core
Oman Medical JournalRespiratory syncytial virus (RSV) infection poses a significant health threat to infants and young children. Considering the substantial burden in Gulf Cooperation Council (GCC) countries, prevention of RSV remains a major public health priority ...
Adel S. Alharbi +7 more
doaj +1 more source
Structural elucidation of the interactions between F glycoprotein and palivizumab.
, 2019 (a) Predicted structure of the RSV-A postfusion F glycoprotein (PDB: 3RRT) bound to palivizumab Fab fragment (PBD: 2HWZ). Pink dots, antigenic site II (amino acid residues 258–275); upper panel, side view; lower panel, top view.
Rabih Andary (6387881) +11 more
core +1 more source
Respiratory syncytial virus immunization patterns in Germany, 2015–2020
Human Vaccines & ImmunotherapeuticsRespiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) in infants and young children worldwide. Using routine statutory health insurance claims data including patients from all regions of Germany, we investigated
Moritz Wick +8 more
doaj +1 more source